Literature DB >> 1850330

Effects of quinapril, a new angiotensin converting enzyme inhibitor, on left ventricular failure and survival in the cardiomyopathic hamster. Hemodynamic, morphological, and biochemical correlates.

S J Haleen1, R E Weishaar, R W Overhiser, R F Bousley, J A Keiser, S R Rapundalo, D G Taylor.   

Abstract

The effect of chronic therapy with quinapril on the temporal progression of left ventricular failure and survival was assessed in the CHF 146 cardiomyopathic (CM) hamster, which is an idiopathic model of congestive heart failure. Age-matched Golden Syrian (GS) hamsters served as normal controls. Quinapril was administered in the drinking water at average daily doses of 10.2, 112.4, and 222.4 mg/kg/day. In untreated CM hamsters, in vitro left ventricular performance progressively deteriorated with increasing age beginning at roughly 180 days. This decline in left ventricular performance was accompanied by a decrease in coronary flow and an increase in left ventricular volume. Administration of quinapril from 180 to 300 days of age prevented the decline of in vitro left ventricular contractile performance and coronary flow and also reduced the age-dependent increases in left ventricular volume. The cardioprotective effects of quinapril were observed at doses of 112.4 and 222.4 mg/kg/day but not at 10.2 mg/kg/day. Lung angiotensin converting enzyme activity was significantly inhibited by quinapril in GS and CM hamsters at 240 and 300 days of age at all dose levels. In contrast, significant inhibition of ventricular angiotensin converting enzyme activity was observed consistently at doses of 112.4 and 222.4 mg/kg/day quinapril but not at 10.2 mg/kg/day. In the survival protocol, CM and GS hamsters were treated with vehicle or quinapril (100 mg/kg/day) from 180 to 522 days of age. During the initial 210 days of treatment (from 180 to 390 days of age) 78.3% of the vehicle-treated CM hamsters died compared with 27.7% of quinapril-treated CM hamsters. Quinapril increased the median survival time of CM hamsters by 32.9% (112 days). It is concluded that chronic quinapril therapy exerts a significant cardioprotective effect and also increases survival.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1850330     DOI: 10.1161/01.res.68.5.1302

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  5 in total

1.  Effects of losartan on the collagen degradative enzymes in hypertrophic and congestive types of cardiomyopathic hamsters.

Authors:  K Masutomo; N Makino; M S Fushiki
Journal:  Mol Cell Biochem       Date:  2001-08       Impact factor: 3.396

2.  Myocardial electrical propagation in patients with idiopathic dilated cardiomyopathy.

Authors:  K P Anderson; R Walker; P Urie; P R Ershler; R L Lux; S V Karwandee
Journal:  J Clin Invest       Date:  1993-07       Impact factor: 14.808

Review 3.  Quinapril. A reappraisal of its pharmacology and therapeutic efficacy in cardiovascular disorders.

Authors:  G L Plosker; E M Sorkin
Journal:  Drugs       Date:  1994-08       Impact factor: 9.546

Review 4.  Treatment of dystrophinopathic cardiomyopathy: review of the literature and personal results.

Authors:  Luisa Politano; Giovanni Nigro
Journal:  Acta Myol       Date:  2012-05

5.  Protective effects of aspirin from cardiac hypertrophy and oxidative stress in cardiomyopathic hamsters.

Authors:  Rong Wu; David Yin; Nataliya Sadekova; Christian F Deschepper; Jacques de Champlain; Helene Girouard
Journal:  Oxid Med Cell Longev       Date:  2012-07-04       Impact factor: 6.543

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.